Skip to main content

Market Overview

BTIG Turns Neutral On TransEnterix, Says Stock Rally Unsupported By Fundamentals

BTIG Turns Neutral On TransEnterix, Says Stock Rally Unsupported By Fundamentals

Transenterix Inc (NYSE: TRXC) shares have spiked 50 percent in the last week, 71 percent in the last month and 734 percent in the last year.

But one analyst senses diminishing momentum.

The Rating

BTIG analyst Sean Lavin downgraded TransEnterix to Neutral and withdrew his price target.

The Thesis

By Lavin’s assessment, the pop in price reflects no fundamental improvements or risk alleviation around commercialization. He attributes the rise to a long-expected indication expansion, the stock’s addition to the Russell 2000 index, a break beyond the $1-billion market cap or general investor sentiment. (See the analyst's track record here.) 

The unjustified increase may bear or reflect expectations of strong quarterly beats, which gives rise to earnings risk, the analyst said. 

“Senhance is in the early days of its U.S. launch, and while we see encouraging signs for system adoption, we also know that capital equipment sales can be lumpy from quarter to quarter." 

BTIG forecast little room for upside given current revenue expectations, although it has no concerns about the company's overall prospects. 

“We continue to like the company’s fundamentals and still view recent Senhance sales momentum, positive international developments and sustained rapid growth in the overall robotic market as pluses for TRXC,” Lavin said. 

Price Action

TransEnterix shares were falling 8.9 percent to $5.32 at the time of publication midday Thursday.

Related Links:

A New Short Report Claims Transenterix's Senhance System Is A 'Commercial Flop'

How Surgeons Are Responding To TransEnterix's Senhance Following FDA Approval

Photo courtesy of TransEnterix. 

Latest Ratings for TRXC

Jan 2021Ladenburg ThalmannDowngradesBuyNeutral
Aug 2019RBC CapitalDowngradesOutperformSector Perform
May 2019Piper JaffrayInitiates Coverage OnNeutral

View More Analyst Ratings for TRXC
View the Latest Analyst Ratings


Related Articles (TRXC)

View Comments and Join the Discussion!

Posted-In: btig medical devices Sean LavinAnalyst Color Downgrades Health Care Analyst Ratings General Best of Benzinga

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at